Model-based evaluation of the efficacy and safety of nivolumab once every 4 weeks across multiple tumor types

Abstract

The benefit-risk profile for nivolumab 480 mg Q4W was predicted to be similar to that of 3 mg/kg Q2W across tumor types while providing a convenient and flexible option for patients and their caregivers.